Argus Raises Amgen Price Target to $460

Amgen's price target has been raised by Argus to $460 from $375.

This adjustment is based on backtested results, which are not an indicator of future actual results. The backtesting methodology assumes that XYZ firm would have been able to purchase the securities recommended and that markets were sufficiently liquid.

Backtested performance has inherent limitations and may not reflect actual trading or the effect of material economic and market factors. Trades have not actually been executed, and results may under- or over-compensate for certain market factors.